Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug shortage

NCCN Survey Persistent Cancer Drug Shortages

Analysis based on 6 articles · First reported Sep 10, 2026 · Last updated Sep 14, 2026

Sentiment
-10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The persistent shortages of low-margin generic oncology drugs highlight fragile sterile-injectable supply chains and could weigh on hospital and cancer-center operating costs, treatment capacity, and margins. Policy responses such as the FDA import relaxation from India may modestly ease near-term supply, but the structural lack of manufacturing incentives keeps downside risk for generic drugmakers and healthcare providers in focus.

pharmaceuticals healthcare oncology

The National Comprehensive Cancer Network published updated survey data on generic cancer medication shortages in the United States, based on responses from pharmacy directors and clinical leadership at its member institutions collected in late August 2026. All responding cancer centers reported a shortage of at least one anti-cancer agent, with more than 20% short of five or more medications. Ifosfamide was in short supply at 94% of centers, carboplatin at 71%, cisplatin at 16%, and the immunotherapy Bacillus Calmette-Guerin at more than half. NCCN has tracked the issue since June 2023, and 96% of pharmacy directors said national or state policies have not improved the situation. Centers have adopted mitigation strategies such as waste management, alternative regimens, and repeat prior authorizations, which delay care. The United States — Food and Drug Administration recently announced a temporary relaxation of import restrictions on supplies from India to help relieve the shortage. NCCN is part of the End Cancer Drug Shortages Coalition, which issued a May 2026 consensus statement urging supply-chain transparency, manufacturing incentives, and generic market stabilization. NCCN CEO Crystal S. Denlinger called the persistence of shortages disheartening, while chief medical officer Renuka Iyer noted the same drugs and issues recur. H. Lee Moffitt Cancer Center & Research Institute and Roswell Park Comprehensive Cancer Center were cited among members managing the problem, with Irvin Alfonso of Moffitt describing inventory and supplier strategies that left it with only one active critical shortage.

ngo
NCCN published the survey data that anchors this event and leads advocacy through the End Cancer Drug Shortages Coalition. Its findings reinforce its policy influence but also highlight an unresolved systemic problem.
Importance 100.0 Sentiment 0.0
govactor
The FDA relaxed import restrictions on supplies from India to help relieve the shortage, a targeted regulatory action that may ease near-term availability of key generics.
Importance 60.0 Sentiment 0.0
cnt
The shortages affect cancer care across the United States, with 96% of surveyed pharmacy directors saying national or state policies have not improved the situation.
Importance 55.0 Sentiment -5.0
cnt
India is a key overseas supplier of generic sterile injectables, and the FDA import relaxation could increase its export volumes to the United States.
Importance 40.0 Sentiment 5.0
per
As NCCN CEO, Denlinger publicly highlighted the persistence of shortages and the strain mitigation efforts place on the cancer care system.
Importance 35.0 Sentiment 0.0
per
NCCN chief medical officer Iyer described the recurring shortages of the same generic drugs and their impact on treatment planning and scheduling.
Importance 30.0 Sentiment 0.0
per
NCCN Vice President of Policy and Advocacy Schatz called for economic incentives for high-quality generic manufacturing and better supplier transparency.
Importance 25.0 Sentiment 0.0
priv
Roswell Park is the institution of NCCN chief medical officer Renuka Iyer, whose comments framed the recurring nature of the shortages.
Importance 20.0 Sentiment 0.0
per
Moffitt inpatient pharmacy director Alfonso detailed inventory reserves and procurement strategies that kept drug availability from becoming a barrier to care.
Importance 20.0 Sentiment 5.0
United States strategic partners ↔ India The United States considers India a vital strategic and economic partner, actively pursuing defense and trade agreements
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.